Sai Life Sciences is a full-service CDMO driven by a vision to support the launch of 25 new medicines by 2025. It works with innovator pharma and biotechcompanies globally, accelerating the discovery, development and manufacture ofcomplex small molecules. A pure-play CDMO, Sai Life Sciences has served adiverse set of NCE development programs, consistently delivering value based onits quality and responsiveness. Today, it works with 7 of the top 10 largepharma companies, as well as several small and mid-sized pharma & biotechcompanies. Sai Life Sciences is privately held and backed by global investors,TPG Capital and HBM Healthcare Investments